Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus

Hypertension

Volumn 45, Issue 4 SUPPL., 2005, Pages 659-665

  Rizzoni, Damiano ^a   Porteri, Enzo ^a   De Ciuceis, Carolina ^a   Sleiman, Intissar ^a   Rodella, Luigi ^a   Rezzani, Rita ^a   Paiardi, Silvia ^a   Bianchi, Rossella ^a   Ruggeri, Giuseppina ^a   Boari, Gianluca E M ^a   Muiesan, Maria Lorenza ^a   Salvetti, Massimo ^a   Zani, Francesca ^a   Miclini, Marco ^a   Rosei, Enrico Agabiti ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Arteries; Diabetes mellitus; Hypertrophy; Remodeling

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GELATINASE B;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SKIN BIOPSY; SUBCUTANEOUS FAT; VASCULARIZATION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIES; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; ENALAPRIL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SUBCUTANEOUS TISSUE; TETRAZOLES;

EID: 20144380571     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000153308.91043.97     Document Type: Conference Paper

References (32)

1. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest ?) form of target organ damage in mild essential hypertension. J Hypertens. 2001;19:921-930.
2. Rizzoni D, Porteri E, Boari GEM, De Ciuceis C, Sleiman I, Muiesan ML, Castellano M, Miclini M, Agabiti-Rosei E. Prognostic significance of small artery structure in hypertension. Circulation. 2003;108:2230-2235.
3. Rizzoni D, Palombo C, Porteri E, Muiesan ML, Kozàkovà M, La Canna G, Nardi M, Guelfi D, Solvetti M, Morizzo C, Vittone F, Agabiti Rosei E. Relationships between coronary flow vasodilator capacity and small artery remodeling in hypertensive patients. J Hypertens. 2003;21:625-632.
4. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, Girelli A, Rodella L, Bianchi R, Sleiman I, Agabiti Rosei E. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non insulin dependent diabetes mellitus. Circulation. 2001;103:1238-1244.
5. Heagerty AM, Aalkjaaer C., Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension. Dual process of remodeling and growth. Hypertension. 1993;21:391-397.
6. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, Giulini SM, Agabiti Rosei E. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension. 1996;28:785-790.
7. Rizzoni D, Porteri E, Giustina A, De Ciuceis C, Sleiman I, Boari GEM, Castellano M, Muiesan ML, Bonadonna S, Burattin A, Cerudelli B, Agabiti Rosei E. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension. 2004;43:1-5.
8. Intengan HD, Schiffrin EL. Vascular remodelling in hypertension. Role of apoptosis, inflammation and fibrosis. Hypertension. 2001;38(Part 2):581-587.
9. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000;36:312-318.
10. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83-91.
11. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995;25(Part 1):474-481.
12. Schiffrin EL, Park JB, Integan HD, Toyuz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonists losartan. Circulation. 2000;101:1653-1659.
13. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 2002;20:71-78.
14. Rizzoni D, Muiesan ML, Porteri E, Castellano M, Zulli R, Bettoni G, Salvetti M, Monteduro C, Agabiti Rosei E. Effects of long-term antihypertensive treament with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens. 1997;15:197-204.
15. Endeman DH, Pu Q, De Ciuceis C, Savoia C, Virdis A, Neves MF, Touyz RM, Schiffrin EL. Persistent remodeling of resistance arteries in type 2 diabetic patients on hypertensive treatment. Hypertension. 2004;43(Pt 2):399-404.
16. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martiez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J. Serum carboxy-terminal propetide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-1735.
17. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL Diez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in the assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286-291.
18. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535-540.
19. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512-2517.
20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1201.
21. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151-183.
22. Mulvany MJ, Hansen PK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res. 1978;43:854-864.
23. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev. 1990;70:921-971.
24. 1B-adrenergic receptor in mice. Circulation. 2002;105:1700-1707.
25. Vranes D, Cooper ME, Dilley RJ. Cellular mechanisms of diabetic vascular hypertrophy. Microvasc Res. 1999;57:8-18.
26. Rizzoni D, Rossi GP, Ported E, Sticchi E, Rodella L, Rezzani R, Sleiman I, De Ciuceis C, Paiardi S, Bianchi R, Nussdorfer GG, Agabiti Rosei E. Bradykinin and matrix metalloproteinases are involved in prevention of structural alterations of rat small arteries during inhibition of ACE and NEP. J Hypertens. 2004;22:1-8.
27. Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
28. Muiesan ML, Pasini GF, Salvetti M, Calebich S, Zulli R, Castellano M; Rizzoni D, Bettoni G, Cinelli A, Porterii E, Corsetti V, Agabiti Rosei E. Cardiac and vascular structural changes. Prevalence and relation to ambulatory blood pressure in a middle-aged general population in northern Italy: The Vobarno Study. Hypertension. 1996;27:1046-1052.
29. Schofield I, Malik R, Izzard A, Austin C, Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus. Evidence for the role of abnormal myogenic responsiveness and dyslipidemia. Circulation. 2002;106:3037-3043.
30. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension. 2001;38:1222-1226.
31. Schiffrin EL, and Hayoz D. How to assess vascular remodelling in small and medium-sized muscular arteries in humans. J Hypertens. 1997;15:571-584.
32. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a β-blocker. Am J Hypertens. 1995;8:229-236.